Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II / Phase III
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
A trial testing whether an oral cholesterol-lowering drug is safe and effective in children and teenagers with familial high cholesterol.
23 Apr 2026 NCT07058077
active not recruiting Phase III Oncology
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Osimertinib after surgery improves survival in early-stage lung cancer patients with specific EGFR mutations.
23 Apr 2026 NCT05120349
active not recruiting Phase II / Phase III
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Mitapivat tested in sickle cell patients to increase haemoglobin levels and reduce painful crisis episodes compared to placebo.
23 Apr 2026 NCT05031780
active not recruiting Phase II
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Trial testing tebapivat against placebo in sickle cell disease patients to find the best dose for improving hemoglobin levels.
23 Apr 2026 NCT06924970
active not recruiting Rheumatology
The UK ADAPTIS Study
Study evaluating a new ankle replacement implant design in NHS patients to assess its performance and durability.
23 Apr 2026 NCT06941558
● Recruiting Phase III Gastroenterology
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Trial testing a new drug (Afimkibart) for treating moderate-to-severe ulcerative colitis in children, measuring safety and effectiveness.
23 Apr 2026 NCT07158242
active not recruiting Phase II Rheumatology
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
A new drug (LY3871801) is being tested for safety and effectiveness in adults with moderate-to-severe rheumatoid arthritis.
23 Apr 2026 NCT05848258
● Recruiting Phase III Respiratory / COPD / Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
What is being tested: Depemokimab, a monoclonal antibody, is being evaluated for its effects on airway structure and function in asthma patients using imaging…
23 Apr 2026 NCT06979323
● Recruiting Phase II Respiratory / COPD / Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
What is being tested: KT-621, an oral investigational agent, is being evaluated in a Phase 2b trial to assess its safety and efficacy in…
23 Apr 2026 NCT07323654
● Recruiting Phase IV Respiratory / COPD / Asthma
Dosing of Steroids for Acute Asthma Given in the Emergency Department – a Pilot Randomised Feasibility Trial of Dexamethasone in Children
What is being tested: A pilot feasibility trial comparing dexamethasone (single-dose steroid) versus standard oral steroids for treating acute asthma exacerbations in children presenting…
23 Apr 2026 NCT07402707
● Recruiting Phase II Oncology
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
What is being tested: The efficacy and safety of combined trastuzumab and pertuzumab (two HER2-targeted monoclonal antibodies) across multiple cancer types with HER2 amplification…
23 Apr 2026 NCT05786716
● Recruiting Phase II Infectious Disease
A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection
What is being tested: Extended high-dose antibiotic treatment combined with methenamine hippurate versus standard care (low-dose prophylactic antibiotics or methenamine hippurate alone) for managing…
23 Apr 2026 NCT07202949
● Recruiting Cardiology / Cardiovascular
Structured Review: To Optimise Management and Prevent Harm in COPD
What is being tested: A structured review intervention designed to optimise COPD management and prevent harm, focusing on reducing exacerbations and improving outcomes in…
23 Apr 2026 NCT07460154
● Recruiting Phase I Oncology
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
What is being tested: GTAEXS617 (REC-617), a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced…
23 Apr 2026 NCT05985655
● Recruiting Phase I Oncology
Study of STP938 in Advanced Solid Tumours
What is being tested: STP938 is an investigational drug being evaluated in a Phase 1 dose escalation and safety expansion study as a monotherapy…
23 Apr 2026 NCT06297525
● Recruiting Phase III Oncology
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Treatment being tested: Sonrotoclax (a BCL2 inhibitor) combined with zanubrutinib (a BTK inhibitor) versus placebo plus zanubrutinib alone in adults with relapsed/refractory mantle cell…
23 Apr 2026 NCT06742996
● Recruiting Phase III Oncology
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
What is being tested: Sacituzumab tirumotecan (an antibody-drug conjugate targeting Trop-2) compared against standard chemotherapy (docetaxel or pemetrexed) in previously-treated advanced/metastatic nonsquamous NSCLC patients…
23 Apr 2026 NCT06074588
● Recruiting Phase I Oncology
Study for AZD4360 in Participants With Advanced Solid Tumours
What is being tested: AZD4360, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced…
23 Apr 2026 NCT06921928
● Recruiting Phase II Oncology
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
What is being tested: Novel agents or novel combination therapies administered perioperatively (before and after surgery) in patients with locally advanced resectable gastric, gastroesophageal…
23 Apr 2026 NCT07069712
● Recruiting Phase III Oncology
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Treatment being tested: Durvalumab combined with domvanalimab (a novel anti-CTLA-4 immune checkpoint inhibitor) versus durvalumab alone, given after concurrent chemoradiation in patients with unresectable…
23 Apr 2026 NCT05211895
active not recruiting Phase III
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Imlifidase allows highly sensitized kidney transplant patients with positive crossmatch to receive transplants safely, with good one-year graft survival.
22 Apr 2026 NCT05369975
● Recruiting Phase I / Phase II
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
ADX-038, a new drug for rare blood disorder PNH, was tested for safety and effectiveness in healthy people and patients.
22 Apr 2026 NCT05876312
● Recruiting Phase III Mental Health / Psychiatry
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
New psilocin-based drug CYB003 tested against placebo for treating depression as an add-on therapy.
22 Apr 2026 NCT06793397
● Recruiting Phase II
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease
New drug IMVT-1402 tested against placebo in adults with Graves' disease uncontrolled by standard thyroid medications.
22 Apr 2026 NCT06727604
● Recruiting Phase II
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Momelotinib tested for safety and effectiveness in reducing blood transfusion needs in early-stage myelodysplastic syndrome patients.
22 Apr 2026 NCT06847867
active not recruiting Rheumatology
Persona Partial Knee Clinical Outcomes Study
Persona Partial Knee implants show good survival rates and clinical outcomes in patients needing partial knee replacement surgery.
22 Apr 2026 NCT03034811
active not recruiting Phase III
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Ianalumab added to steroids didn't improve platelet counts better than steroids alone in newly diagnosed ITP patients.
22 Apr 2026 NCT05653349
active not recruiting Rheumatology
JIA Toolbox Feasibility Study
Testing three prototype tools to help children with juvenile arthritis manage daily activities more independently and effectively.
22 Apr 2026 NCT07543575
● Recruiting Phase I Neurology
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Treatment being tested: AZD0120, a dual-targeting CAR-T cell therapy designed to target both BCMA and CD19 on B cells, being evaluated for safety and…
22 Apr 2026 NCT07224373
● Recruiting Phase II
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
ALXN1920 (a complement C3 inhibitor) is being tested against placebo in adults with primary membranous nephropathy, with efficacy measured by reduction in 24-hour urine…
22 Apr 2026 NCT07157787
● Recruiting Phase II
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Drug being tested: ADX-038, a novel therapeutic agent targeting complement-mediated pathways, is being evaluated for safety, efficacy, and how the body processes and responds…
22 Apr 2026 NCT06989359
● Recruiting Respiratory / COPD / Asthma
The Physiotherapy Assessment of Breathing Pattern Disorder
What is being tested: The study evaluates the Breathing Pattern Assessment Tool (BPAT), a clinical assessment instrument designed by physiotherapists to diagnose and characterise…
22 Apr 2026 NCT07543588
● Recruiting Phase III Oncology
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Drug being tested: GSK5764227 (Risvutatug rezetecan/Ris-Rez) is a novel B7-H3-targeted therapy designed to inhibit cancer cell growth and metastasis in patients with relapsed small…
22 Apr 2026 NCT07099898
● Recruiting Phase III Cardiology / Cardiovascular
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial – Part 2
What is being tested: Recombinant Factor VIIa (rFVIIa) as a potential therapeutic intervention to halt hematoma expansion and improve outcomes in patients with acute…
22 Apr 2026 NCT07227246
● Recruiting Cardiology / Cardiovascular
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Device Being Tested: The Shockwave Reducer, a coronary sinus reducer device designed to increase coronary perfusion pressure and improve myocardial blood flow in patients…
22 Apr 2026 NCT05102019
● Recruiting Phase III Cardiology / Cardiovascular
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
What is being tested: ADX-324, a novel therapeutic agent, is being evaluated in a Phase 3 trial to assess its efficacy and safety in…
22 Apr 2026 NCT06960213
● Recruiting Cardiology / Cardiovascular
Collection of Blood Samples for New Diagnostic Devices 2
What is being tested: Development and validation of new diagnostic biomarkers on the LumiraDx Platform, with comparative evaluation against established gold standard reference methods…
22 Apr 2026 NCT05568966
● Recruiting Phase I Oncology
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Drug Being Tested: NDI-219216, a novel investigational agent being evaluated for safety, tolerability, and efficacy in patients with advanced solid tumours through a phased…
22 Apr 2026 NCT06898450
● Recruiting Phase III Oncology
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What is being tested: BGB-16673, a novel BTK inhibitor, is being evaluated against pirtobrutinib (an established BTK inhibitor) in patients with relapsed/refractory CLL or…
22 Apr 2026 NCT06973187
● Recruiting Phase III Oncology
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
What is being tested: This Phase 3 trial compares belantamab mafodotin combined with lenalidomide and dexamethasone (BRd) against daratumumab combined with lenalidomide and dexamethasone…
22 Apr 2026 NCT06679101
● Recruiting Phase III Oncology
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Treatment being tested: IMVT-1402, a novel therapeutic agent, is being evaluated for efficacy, safety and tolerability in adults with generalized myasthenia gravis across mild…
22 Apr 2026 NCT07039916
● Recruiting Phase III Oncology
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
What is being tested: Zanubrutinib (a Bruton tyrosine kinase inhibitor) combined with obinutuzumab (anti-CD20 monoclonal antibody) versus the standard regimen of lenalidomide plus rituximab…
22 Apr 2026 NCT05100862
● Recruiting Phase III Oncology
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
What is being tested: A novel oral cladribine formulation is being evaluated against placebo for efficacy and safety in treating generalized myasthenia gravis (gMG),…
22 Apr 2026 NCT06463587
● Recruiting Phase III Oncology
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)
Treatment being tested: Petosemtamab (a fibroblast activation protein inhibitor) combined with pembrolizumab compared to pembrolizumab monotherapy as first-line treatment for recurrent or metastatic head…
22 Apr 2026 NCT06525220
● Recruiting Phase II
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
AGA2115 tested against placebo in adults with osteogenesis imperfecta caused by COL1A1 or COL1A2 gene mutations.
21 Apr 2026 NCT07062588
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
A new drug (claseprubart) tested against placebo in adults with chronic inflammatory demyelinating polyneuropathy to assess whether it works and is safe.
21 Apr 2026 NCT06858579
active not recruiting Rheumatology
Resistance Exercise Training to Improve Bone and Articular Cartilage Health in Women
Resistance exercise with varying intensity and speed improves bone density, cartilage health, and muscle strength in women.
21 Apr 2026 NCT05889598
active not recruiting Phase III
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
ALXN1720 (a complement inhibitor) was tested for safety and effectiveness in treating autoimmune myasthenia gravis in adults.
21 Apr 2026 NCT05556096
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Anifrolumab injection added to standard treatment improved muscle disease activity in adults with polymyositis and dermatomyositis compared to placebo.
21 Apr 2026 NCT06455449
active not recruiting Rheumatology
Comprehensive Nano – Post Market Clinical Follow-Up Study
Single-arm study tracking long-term safety and effectiveness outcomes of Comprehensive Nano devices to meet regulatory requirements.
21 Apr 2026 NCT03423953